Chugai Gets Third US Breakthrough Status, For Hemophilia Antibody
This article was originally published in PharmAsia News
The US FDA has designated Chugai’s ACE910 as a breakthrough therapy for hemophilia A, making the bispecific antibody the first hemophilia treatment to receive the expedited review status, and marking the third project from the Japanese firm to receive the classification.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.